Trial Profile
Randomised phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OCTOVA
- 22 Feb 2022 Planned End Date changed from 30 Jun 2021 to 30 Jun 2022.
- 01 Jul 2021 Status changed from active, no longer recruiting to completed.
- 21 Nov 2019 Planned End Date changed from 30 Nov 2021 to 30 Jun 2021.